Revolution Medicines Inc
NASDAQ:RVMD
Revolution Medicines Inc
NASDAQ:RVMD
Price:
38.95 USD
-1.12%
Updated:
May 16, 2024
P/E
Price to Earnings
Price to Earnings
-13.3
Current
-9.9
Median
27.4
Industry
Lower
than median
Lower
than industry value
Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.
P/E
=-13.3
Market Cap
/
6.4B
Net Income
-484.3m
All Countries
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| US |
|
Revolution Medicines Inc
NASDAQ:RVMD
|
6.4B USD | -13.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
287.2B USD | 59.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
167.6B USD | 44.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112.5B USD | 31.1 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
107.4B USD | 27.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
138.6B AUD | 37.6 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
84.1B USD | 173.8 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
50.3B USD | -8.4 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | -57.5 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
33.3B USD | 28.5 | |
| KR |
|
Celltrion Inc
KRX:068270
|
40T KRW | 74.7 |
P/E Forward Multiples
Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/E
-12
2-Years Forward
P/E
-11
3-Years Forward
P/E
-11.5
You don't have any saved screeners yet
